ImmunityBio, Inc. Common Stock
$8.48
$0.02 (+0.24%)
$8.20Day Range$8.53
Key Statistics
Market Cap
$8.97B
Shares Outstanding
1,059.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 10, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$8.46
Day High
$8.53
Day Low
$8.20
Volume
18.43M
VWAP
$8.44
Prev Close
$8.46
Transactions
--
Acc. Volume
--
About ImmunityBio, Inc. Common Stock
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836691 employees3530 JOHN HOPKINS COURT, SAN DIEGO, CA, 92121(844) 696-5235IPO Mar 10, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001326110
- Composite FIGI
- BBG007T9DYW9
- Share Class FIGI
- BBG007T9DYX8
- Ticker Root
- IBRX
- SIC Code
- 2836
About ImmunityBio, Inc. Common Stock (IBRX) Stock
ImmunityBio, Inc. Common Stock (IBRX) closed the 2026-09-18 session at $8.48, up 0.24% versus the previous close (+0.02). The stock opened at $8.46 and traded between $8.20 and $8.53 during that session. Session trading volume was 18.4M shares. The volume-weighted average price (VWAP) is $8.44.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
ImmunityBio, Inc. Common Stock has a market capitalization of $8.97 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. IBRX is listed on the XNAS exchange. The company employs approximately 691 people. ImmunityBio, Inc. Common Stock is headquartered in SAN DIEGO, CA. The recorded listing date is 2021-03-10.
On this page you can find market IBRX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.